α干扰素合并羟基脲治疗慢性粒细胞性白血病的疗效探讨  

Evaluation of clinical effectiveness of combination therapy with interferon-alpha and hydroxyurea in patients with chronic myelogenous leukemia

作　　者：吴文[1] 沈志祥[1] 陈钰[1] 曾晓颖[1] 李军民[1] 

机构地区：[1]上海第二医科大学附属瑞金医院血液科,200025

出　　处：《上海医学》2001年第5期285-287,共3页Shanghai Medical Journal

摘　　要：目的　探讨α干扰素 (INF)合并羟基脲治疗慢性粒细胞性白血病的临床疗效。方法　慢性粒细胞性白血病慢性期患者 5 1例 [Ph1(+)、bcr abl融合基因 (+) ],接受α 2b干扰素 3MU ,隔日皮下注射 ,根据外周血白细胞计数决定 +/ -羟基脲治疗。 34例患者经 9个月或以上随访。结果　 5 1例患者初发病时白细胞 (WBC)(134 .5 7± 119.49)× 10 9/L ,所有患者经 3个月治疗后均达到完全临床缓解 ,WBC (6 .46± 2 .2 3)× 10 9/L。 34例INF治疗 9个月或以上的患者中 ,8例Ph1染色体消失 ,Ph1抑制率达 2 3.5 % (8/ 34 )。 8例Ph1染色体转阴的病例中 ,3例bcr abl融合基因转为 (- )。以上 34例患者中 3例于 12个月急变。结论　INF合并羟基脲治疗慢性粒细胞性白血病 ,CR率高 ,可以减少Ph1阳性克隆细胞 ,是一种较为安全有效的治疗方法。Objective To explore the clinical effectiveness of combination therapy with interferon α and hydroxyurea in patients with chronic myelogenous leukemia. Methods Fifty one patients of CML (chronic phase) were treated with interferon α 2b, subcutaneous injection 3 MU every two days. According to WBC, +/- hydroxyurea treatment. The follow up period after interferon therapy in 34 cases was more than 9 months. Results At the beginning of the episode, the WBC of 51 cases was (134.57±119.49)×10 9/L. After 3 months of treatment, all of them achieved complete clinical remission, the WBC was (6.46±2.23)×10 9/L. Thirty four of the total cases were treated longer than 9 months. Philadelphia chromosome transferred to negative in 8 of them. The rate of Ph 1 inhibition was 23.5% (8/34). Bcr abl fuse gene transferred to negative in 3 cases. 3 of the 34 cases deteriorated to acute phase after 12 months of treatment. Conclusion The combination therapy with interferon alpha and hydroxyurea for chronic myelogenous leukemia is relatively safe and effective.

关 键 词：慢性粒细胞性白血病 αINF Α干扰素 羟基脲 疗效 治疗 

分 类 号：R733.7[医药卫生—肿瘤]